Latest Insider Transactions at Fusion Pharmaceuticals Inc. (FUSN)
This section provides a real-time view of insider transactions for Fusion Pharmaceuticals Inc. (FUSN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Fusion Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Fusion Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,898
-1.01%
|
$34,286
$7.88 P/Share
|
|
Feb 17
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,700
-0.35%
|
$11,900
$7.98 P/Share
|
|
Feb 16
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,202
-6.39%
|
$232,414
$7.99 P/Share
|
|
Feb 15
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,600
-2.37%
|
$100,800
$8.33 P/Share
|
|
Aug 31
2021
|
John J Crowley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,910
+27.3%
|
-
|
|
Aug 31
2021
|
James J O'Leary Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,722
+45.99%
|
-
|
|
Aug 23
2021
|
Steven Gannon |
BUY
Open market or private purchase
|
Direct |
2,829
+19.08%
|
$19,803
$7.99 P/Share
|
|
Aug 19
2021
|
Steven Gannon |
BUY
Open market or private purchase
|
Direct |
3,000
+24.65%
|
$24,000
$8.05 P/Share
|
|
Aug 18
2021
|
Steven Gannon |
BUY
Open market or private purchase
|
Direct |
171
+2.7%
|
$1,368
$8.05 P/Share
|
|
Aug 16
2021
|
Steven Gannon |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$48,000
$8.1 P/Share
|
|
Dec 24
2020
|
Adams Street Partners LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,800
-0.11%
|
$45,600
$12.32 P/Share
|
|
Dec 23
2020
|
Adams Street Partners LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,569
-0.13%
|
$54,828
$12.39 P/Share
|
|
Jun 30
2020
|
Adams Street Partners LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,502,425
+36.15%
|
-
|
|
Jun 30
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
898,000
+34.71%
|
$15,266,000
$17.0 P/Share
|
|
Jun 30
2020
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,224,770
+50.0%
|
-
|
|
Jun 30
2020
|
Johnson & Johnson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
725,000
+16.49%
|
$12,325,000
$17.0 P/Share
|
|
Jun 30
2020
|
Johnson & Johnson > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,945,516
+50.0%
|
-
|